Ubs Asset Management Americas Inc Cullinan Oncology, Inc. Transaction History
Ubs Asset Management Americas Inc
- $381 Billion
- Q3 2024
A detailed history of Ubs Asset Management Americas Inc transactions in Cullinan Oncology, Inc. stock. As of the latest transaction made, Ubs Asset Management Americas Inc holds 70,911 shares of CGEM stock, worth $776,475. This represents 0.0% of its overall portfolio holdings.
Number of Shares
70,911
Previous 68,534
3.47%
Holding current value
$776,475
Previous $1.2 Million
0.67%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding CGEM
# of Institutions
146Shares Held
67.6MCall Options Held
612KPut Options Held
118K-
Bio Impact Capital LLC Cambridge, MA7.65MShares$83.7 Million19.97% of portfolio
-
Bvf Inc San Francisco, CA5.75MShares$63 Million3.06% of portfolio
-
Black Rock Inc. New York, NY3.55MShares$38.9 Million0.0% of portfolio
-
Chi Advisors LLC New York, NY3.41MShares$37.4 Million15.23% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY3.28MShares$35.9 Million1.02% of portfolio
About Cullinan Oncology, Inc.
- Ticker CGEM
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 45,612,200
- Market Cap $499M
- Description
- Cullinan Oncology Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with ...